Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Expanding Access to Affordable Prescription Drugs and Medical Devices Act
Client: MEDICINES360 · Firm: WAXMAN STRATEGIES
Support for non-profit pharmaceutical manufacturers, S. 2257
Expanding Access to Affordable Prescription Drugs and Medical Devices Act
Client: MEDICINES360 · Firm: WAXMAN STRATEGIES
Support for non-profit pharmaceutical manufacturers, S. 2257
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
340B HEALTH via WAXMAN STRATEGIES
2026 · third_quarter · Q3
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Issues affecting the 340B drug pricing program; appropriations for 340B program
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Source: Senate LDA
2026 · second_quarter · Q2
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Issues affecting the 340B drug pricing program; appropriations for 340B program
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
340B HEALTH via WAXMAN STRATEGIES
2026 · first_quarter · 1A
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Issues affecting the 340B drug pricing program; appropriations for 340B program
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
340B HEALTH via WAXMAN STRATEGIES
2026 · first_quarter · Q1
Issues affecting the 340B drug pricing program, drug prices, and health care costs
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
340B HEALTH via WAXMAN STRATEGIES
2025 · fourth_quarter · Q4
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
340B HEALTH via WAXMAN STRATEGIES
2025 · third_quarter · Q3
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
340B HEALTH via WAXMAN STRATEGIES
2025 · second_quarter · Q2
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
340B HEALTH via WAXMAN STRATEGIES
2025 · first_quarter · Q1
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
340B HEALTH via WAXMAN STRATEGIES
2024 · fourth_quarter · Q4
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
340B HEALTH via WAXMAN STRATEGIES
2024 · third_quarter · Q3
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
340B HEALTH via WAXMAN STRATEGIES
2024 · second_quarter · Q2
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
340B HEALTH via WAXMAN STRATEGIES
2024 · first_quarter · Q1
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
340B HEALTH via WAXMAN STRATEGIES
2023 · fourth_quarter · Q4
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
340B HEALTH via WAXMAN STRATEGIES
2023 · third_quarter · Q3
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
340B HEALTH via WAXMAN STRATEGIES
2023 · second_quarter · Q2
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
340B HEALTH via WAXMAN STRATEGIES
2023 · first_quarter · Q1
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
340B HEALTH via WAXMAN STRATEGIES
2022 · fourth_quarter · Q4
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
340B HEALTH via WAXMAN STRATEGIES
2022 · third_quarter · Q3
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
340B HEALTH via WAXMAN STRATEGIES
2022 · second_quarter · Q2
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
340B HEALTH via WAXMAN STRATEGIES
2022 · first_quarter · Q1
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MEDICINES360 via WAXMAN STRATEGIES
2021 · fourth_quarter · Q4
Support for non-profit pharmaceutical manufacturers, S. 2257
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
340B HEALTH via WAXMAN STRATEGIES
2021 · fourth_quarter · Q4
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MEDICINES360 via WAXMAN STRATEGIES
2021 · third_quarter · Q3
Support for non-profit pharmaceutical manufacturers, S. 2257
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
340B HEALTH via WAXMAN STRATEGIES
2021 · third_quarter · Q3
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
340B HEALTH via WAXMAN STRATEGIES
2021 · second_quarter · Q2
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
340B HEALTH via WAXMAN STRATEGIES
2021 · first_quarter · 1A
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
340B HEALTH via WAXMAN STRATEGIES
2021 · first_quarter · Q1
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
340B HEALTH via WAXMAN STRATEGIES
2020 · fourth_quarter · Q4
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE